Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 19 studies | 57% ± 16% | |
lung | 18 studies | 48% ± 22% | |
intestine | 13 studies | 40% ± 20% | |
kidney | 9 studies | 59% ± 19% | |
eye | 9 studies | 37% ± 14% | |
lymph node | 7 studies | 58% ± 22% | |
liver | 7 studies | 32% ± 9% | |
uterus | 6 studies | 57% ± 28% | |
brain | 5 studies | 29% ± 15% | |
bone marrow | 5 studies | 41% ± 18% | |
placenta | 4 studies | 75% ± 28% | |
prostate | 4 studies | 62% ± 15% | |
breast | 4 studies | 53% ± 9% | |
pancreas | 3 studies | 56% ± 29% | |
ovary | 3 studies | 33% ± 9% | |
adrenal gland | 3 studies | 55% ± 14% | |
esophagus | 3 studies | 50% ± 24% | |
skin | 3 studies | 43% ± 14% | |
thymus | 3 studies | 60% ± 18% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
intestine | 91% | 44.99 | 881 / 966 | 25% | 1.02 | 134 / 527 |
bladder | 100% | 55.52 | 21 / 21 | 12% | 0.43 | 62 / 504 |
stomach | 92% | 40.62 | 330 / 359 | 13% | 0.50 | 38 / 286 |
ovary | 97% | 50.04 | 174 / 180 | 5% | 0.06 | 20 / 430 |
esophagus | 95% | 42.54 | 1371 / 1445 | 6% | 0.08 | 11 / 183 |
kidney | 99% | 54.91 | 88 / 89 | 0% | 0.00 | 1 / 901 |
brain | 99% | 91.11 | 2603 / 2642 | 0% | 0 | 0 / 705 |
adrenal gland | 98% | 43.52 | 254 / 258 | 0% | 0 | 0 / 230 |
prostate | 98% | 60.31 | 240 / 245 | 0% | 0 | 0 / 502 |
thymus | 96% | 39.85 | 628 / 653 | 0% | 0 | 0 / 605 |
uterus | 94% | 40.76 | 159 / 170 | 1% | 0.01 | 3 / 459 |
spleen | 94% | 35.22 | 226 / 241 | 0% | 0 | 0 / 0 |
skin | 91% | 45.84 | 1647 / 1809 | 0% | 0 | 0 / 472 |
breast | 88% | 31.35 | 405 / 459 | 0% | 0 | 0 / 1118 |
pancreas | 87% | 25.76 | 286 / 328 | 0% | 0 | 0 / 178 |
lung | 87% | 32.96 | 500 / 578 | 1% | 0.01 | 7 / 1155 |
blood vessel | 87% | 31.01 | 1156 / 1335 | 0% | 0 | 0 / 0 |
liver | 86% | 47.59 | 195 / 226 | 0% | 0 | 0 / 406 |
heart | 84% | 22.55 | 725 / 861 | 0% | 0 | 0 / 0 |
adipose | 81% | 29.24 | 977 / 1204 | 0% | 0 | 0 / 0 |
muscle | 55% | 10.79 | 445 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 55% | 17.70 | 511 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0042327 | Biological process | positive regulation of phosphorylation |
GO_0002906 | Biological process | negative regulation of mature B cell apoptotic process |
GO_0048146 | Biological process | positive regulation of fibroblast proliferation |
GO_0006954 | Biological process | inflammatory response |
GO_0010629 | Biological process | negative regulation of gene expression |
GO_0045087 | Biological process | innate immune response |
GO_0050918 | Biological process | positive chemotaxis |
GO_0031666 | Biological process | positive regulation of lipopolysaccharide-mediated signaling pathway |
GO_0033138 | Biological process | positive regulation of peptidyl-serine phosphorylation |
GO_0043030 | Biological process | regulation of macrophage activation |
GO_0070207 | Biological process | protein homotrimerization |
GO_0090238 | Biological process | positive regulation of arachidonic acid secretion |
GO_0061081 | Biological process | positive regulation of myeloid leukocyte cytokine production involved in immune response |
GO_0033033 | Biological process | negative regulation of myeloid cell apoptotic process |
GO_2000343 | Biological process | positive regulation of chemokine (C-X-C motif) ligand 2 production |
GO_0051248 | Biological process | negative regulation of protein metabolic process |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0050731 | Biological process | positive regulation of peptidyl-tyrosine phosphorylation |
GO_0010739 | Biological process | positive regulation of protein kinase A signaling |
GO_0030890 | Biological process | positive regulation of B cell proliferation |
GO_0001516 | Biological process | prostaglandin biosynthetic process |
GO_0010760 | Biological process | negative regulation of macrophage chemotaxis |
GO_1902166 | Biological process | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator |
GO_0019752 | Biological process | carboxylic acid metabolic process |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0030336 | Biological process | negative regulation of cell migration |
GO_0090398 | Biological process | cellular senescence |
GO_0001819 | Biological process | positive regulation of cytokine production |
GO_0061078 | Biological process | positive regulation of prostaglandin secretion involved in immune response |
GO_0043518 | Biological process | negative regulation of DNA damage response, signal transduction by p53 class mediator |
GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
GO_0032760 | Biological process | positive regulation of tumor necrosis factor production |
GO_2000773 | Biological process | negative regulation of cellular senescence |
GO_0030330 | Biological process | DNA damage response, signal transduction by p53 class mediator |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0034774 | Cellular component | secretory granule lumen |
GO_0009986 | Cellular component | cell surface |
GO_1904813 | Cellular component | ficolin-1-rich granule lumen |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0031982 | Cellular component | vesicle |
GO_0004167 | Molecular function | dopachrome isomerase activity |
GO_0005126 | Molecular function | cytokine receptor binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0002020 | Molecular function | protease binding |
GO_0042056 | Molecular function | chemoattractant activity |
GO_0050178 | Molecular function | phenylpyruvate tautomerase activity |
GO_0005515 | Molecular function | protein binding |
GO_0005125 | Molecular function | cytokine activity |
Gene name | MIF |
Protein name | Macrophage migration inhibitory factor (MIF) (EC 5.3.2.1) (Glycosylation-inhibiting factor) (GIF) (L-dopachrome isomerase) (L-dopachrome tautomerase) (EC 5.3.3.12) (Phenylpyruvate tautomerase) Macrophage migration inhibitory factor (EC 5.3.2.1) (EC 5.3.3.12) (L-dopachrome isomerase) (L-dopachrome tautomerase) (Phenylpyruvate tautomerase) |
Synonyms | GLIF MMIF |
Description | FUNCTION: Pro-inflammatory cytokine involved in the innate immune response to bacterial pathogens . The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense . Counteracts the anti-inflammatory activity of glucocorticoids . Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known . It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity . . |
Accessions | P14174 ENST00000215754.8 I4AY87 ENST00000613839.2 A6MUU8 |